CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy
dc.contributor.author | Hammad, Nazik | en_US |
dc.contributor.author | Heilbrun, Lance K. | en_US |
dc.contributor.author | Philip, Philip A. | en_US |
dc.contributor.author | Shields, Anthony F. | en_US |
dc.contributor.author | Zalupski, Mark M. | en_US |
dc.contributor.author | Venkatramanamoorthy, Raghu | en_US |
dc.contributor.author | El-Rayes, Bassel F. | en_US |
dc.date.accessioned | 2011-01-31T17:52:11Z | |
dc.date.available | 2011-08-02T18:19:14Z | en_US |
dc.date.issued | 2010-06 | en_US |
dc.identifier.citation | Hammad, Nazik; Heilbrun, Lance K.; Philip, Philip A.; Shields, Anthony F.; Zalupski, Mark M.; Venkatramanamoorthy, Raghu; El-Rayes, Bassel F.; (2010). "CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy." Asia-Pacific Journal of Clinical Oncology 6(2): 98-105. <http://hdl.handle.net/2027.42/79310> | en_US |
dc.identifier.issn | 1743-7555 | en_US |
dc.identifier.issn | 1743-7563 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/79310 | |
dc.description.abstract | The aim of this study was to determine the predictive role of pretreatment carbohydrate antigen 19-9 (CA19-9) measurement and its change after one cycle of gemcitabine-based therapy for response, time to progression (TTP) and overall survival (OS).Analyses were derived from three consecutive gemcitabine-containing phase II clinical trials between 1997 and 2004.A total of 111 patients with pancreas cancer was studied. Baseline CA19-9 concentrations were dichotomized near the median. Lower baseline CA19-9 levels were positively associated with OS (median 9.1 vs 6.1 months, P = 0.0057) and TTP (median 6.4 vs 4.2 months, P = 0.0044).The covariate adjusted hazard ratio (HR) for progression among patients with baseline CA19-9 ≥ 1000 ng/mL was HR = 1.94 (95% CI 1.24–3.02), with P = 0.0035. The covariate adjusted risk of death among patients with baseline CA19-9 ≥ 1000 ng/ml was similarly elevated: HR = 1.90 (95% CI 1.23–2.94), with P = 0.0039. Change in CA19-9 levels from baseline to the end of treatment cycle 1 did not predict objective response ( P = 0.75). There was somewhat longer OS (median 8.7 vs 7.1 months) and TTP (median 7.1 vs 5.4 months) in patients with ≥50% reduction in serum CA19-9 concentrations, but this was not statistically significant ( P = 0.74 and 0.81, respectively).Baseline CA19-9 levels may predict survival in patients with advanced pancreas cancer. The change in CA19-9 levels determined within 1 month of the initiation of therapy did not predict treatment outcome. | en_US |
dc.format.extent | 230436 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Asia | en_US |
dc.subject.other | CA19-9 | en_US |
dc.subject.other | Gemcitabine | en_US |
dc.subject.other | Pancreatic Cancer | en_US |
dc.title | CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Hematology and Oncology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Cancer Center, Ann Arbor, MI and | en_US |
dc.contributor.affiliationother | Karmanos Cancer Institute, Wayne State University, Detroit, | en_US |
dc.contributor.affiliationother | Biostatistics Unit, Karmanos Cancer Institute, Detroit, MI, USA | en_US |
dc.identifier.pmid | 20565421 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/79310/1/j.1743-7563.2010.01290.x.pdf | |
dc.identifier.doi | 10.1111/j.1743-7563.2010.01290.x | en_US |
dc.identifier.source | Asia-Pacific Journal of Clinical Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.